Search results
Results from the WOW.Com Content Network
The 4th Assault Amphibian Battalion (4th AABn) is a mechanized battalion of the United States Marine Corps Reserve.Their primary weapon system is the AAV-P7/A1 (formerly LVTP-7) Amphibious Assault Vehicle and they are part of the 4th Marine Division of the Marine Forces Reserve.
The Assault Amphibious Vehicle [2] [3] (AAV)—official designation AAVP-7A1 (formerly known as Landing Vehicle, Tracked, Personnel-7 abbr. LVTP-7)—is a fully tracked amphibious landing vehicle manufactured by U.S. Combat Systems (previously by United Defense, a former division of FMC Corporation).
Adeno Associated Virus (AAV) (lower panel) – To produce AAV, package a gene of interest into the AAV-ITR vector and transfect cells with a Helper vector and the Rep/Cap DNA integration vector. Adeno-associated viruses (AAVs) are relatively small single-stranded DNA viruses belonging to Parvoviridae and, like lentiviral vectors, AAVs can ...
Self-complementary adeno-associated virus (scAAV) is a viral vector engineered from the naturally occurring adeno-associated virus (AAV) to be used as a tool for gene therapy. [1] Use of recombinant AAV (rAAV) has been successful in clinical trials addressing a variety of diseases. [ 2 ]
The vector itself generally carries a DNA sequence that consists of an insert (in this case the transgene) and a larger sequence that serves as the "backbone" of the vector. The purpose of a vector which transfers genetic information to another cell is typically to isolate, multiply, or express the insert in the target cell.
The drug consists of a MTM1 transgene encapsulated in a viral vector from the adeno-associated virus class (AAV8) and is administered to affected children as an intravenous infusion. The treatment is being developed by Astellas Gene Therapies and is currently in a phase I/II clinical trial in the United States.
The characteristic feature of the adeno-associated virus is a deficiency in replication and thus its inability to multiply in unaffected cells. Adeno-associated virus spreads by co-infecting a cell with a helper virus.
In July results of a gene therapy candidate for haemophilia B called FLT180 were announced, it works using an adeno-associated virus (AAV) to restore the clotting factor IX (FIX) protein, normal levels of the protein were observed with low doses of the therapy but immunosuppression was necessitated to decrease the risk of vector-related immune ...